Evaluation of Clinical and Immune Responses in Recovered Children with Mild COVID-19

Area of Science:

• Pediatrics
• Immunology
• Infectious Diseases

Background:

• COVID-19 (coronavirus disease 2019) disproportionately affects children, with emerging variants.
• Long-term immune memory and health consequences in pediatric COVID-19 remain unclear.
• Understanding post-infection immunity in children is crucial for public health strategies.

Purpose of the Study:

• To investigate the establishment of immune memory and long-term health outcomes in children (0-14 years) after COVID-19.
• To assess persistent lung lesions and immune responses 6-8 months post-symptom onset.
• To compare immune memory development across different pediatric age groups.

Main Methods:

• Collected clinical data and whole blood samples from pediatric COVID-19 patients 6-8 months after symptom onset.
• Analyzed inflammation markers, lung imaging, and antigen-specific antibody (IgG, IgM) and cellular immune responses (T cells, B cells).
• Stratified analysis by age groups: infants/young children (0-4 years) and older children (5-14 years).

Main Results:

• Inflammation signs normalized across all pediatric age groups.
• Persistent lung lesions were observed in 0-4 year olds, with slower IgG secretion.
• Older children (5-14 years) showed gradual lung recovery and the strongest IgG response, alongside robust IgM+ memory B cells and specific T cells in all ages.

Conclusions:

• Infants and young children may experience persistent lung lesions for 6-8 months post-COVID-19.
• Despite lung abnormalities, most children develop detectable neutralizing antibodies and specific cellular immune responses.
• Robust immune memory, including T and B cell responses, is established in children following COVID-19 infection.